Tag: Silo Pharma - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Post published:February 18, 2021
Post category:Press Release

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Post published:February 10, 2021
Post category:Press Release

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Post published:January 26, 2021
Post category:Press Release

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Post published:January 13, 2021
Post category:Press Release

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Post published:January 11, 2021
Post category:Press Release

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Post published:January 6, 2021
Post category:Press Release

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Post published:December 15, 2020
Post category:Press Release

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Post published:December 9, 2020
Post category:Press Release

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Post published:December 7, 2020
Post category:Press Release

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

Post published:December 4, 2020
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.